IP Verse

Elpen Pharmaceutical competitive analysis

Explore patent oppositions filed by Elpen Pharmaceutical against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 16, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 21, 2025
EP3626270	New Use	NOVARTIS	Jul 11, 2024
EP2959894	S1P Receptor Modulators For Treating Multiple Sclerosis	NOVARTIS	Oct 20, 2022

Explore the latest publications and patents granted to Elpen Pharmaceutical, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Elpen Pharmaceutical, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Elpen Pharmaceutical with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 16, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ELPEN PHARMACEUTICAL	3	-	-	-
NOVARTIS	6	422	-	21